Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) EBIT: 2015-2024

Historic EBIT for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$534.3 million.

  • Intellia Therapeutics' EBIT rose 23.00% to -$111.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$478.7 million, marking a year-over-year increase of 10.97%. This contributed to the annual value of -$534.3 million for FY2024, which is 3.68% down from last year.
  • As of FY2024, Intellia Therapeutics' EBIT stood at -$534.3 million, which was down 3.68% from -$515.3 million recorded in FY2023.
  • Intellia Therapeutics' 5-year EBIT high stood at -$136.6 million for FY2020, and its period low was -$534.3 million during FY2024.
  • Moreover, its 3-year median value for EBIT was -$515.3 million (2023), whereas its average is -$502.6 million.
  • Data for Intellia Therapeutics' EBIT shows a maximum YoY slumped of 96.11% (in 2021) over the last 5 years.
  • Intellia Therapeutics' EBIT (Yearly) stood at -$136.6 million in 2020, then crashed by 96.11% to -$267.9 million in 2021, then slumped by 71.05% to -$458.2 million in 2022, then decreased by 12.47% to -$515.3 million in 2023, then dropped by 3.68% to -$534.3 million in 2024.